PEi Program

PEi: Pseudomonas Elastase inhibitors (powered by CARB-X)

Cystic fibrosis (CF) is a life-threatening disease, caused by mutation in the CFTR chloride channel, affecting ~70,000 sufferers worldwide. The majority (>80%) of adult CF patients have acute and chronic Pseudomonas aeruginosa lung infections, due to impaired ciliary clearance, causing progressive and irreversible lung damage resulting in early death.

Antabio’s PEi program, powered by CARB-X, is developing an inhaled drug  targeting a key virulence factor of P. aeruginosa involved in pathogenesis and persistence, to be used as an adjunct to existing antibiotic therapy for the treatment of P. aeruginosa infections in CF patients. Preclinical development is in progress.